問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

Division of General Internal Medicine

Division of Neurology

更新時間：2023-09-19

李旺祚LEE, WANG-TSO
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李旺祚

List

36Cases

2015-01-26 - 2025-06-02

Phase II

An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.

  • Condition/Disease

    Spinal muscular atrophy

  • Test Drug

    ISIS 396443

Participate Sites
2Sites

Terminated2Sites

2015-05-01 - 2022-07-31

Phase III

A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy compared with Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent - Onset Epilepsy.

  • Condition/Disease

    Epilepsy

  • Test Drug

    Topamax F.C. Tablets 25mg, 50mg, 100mg and Topamax Sprinkle Capsule 25mg

Participate Sites
6Sites

Terminated5Sites

周宜卿
China Medical University Hospital-Taipei

未分科

2014-11-03 - 2018-12-31

Phase III

A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

  • Condition/Disease

    PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

  • Test Drug

    PREGABALIN

Participate Sites
3Sites

Terminated3Sites

2014-09-01 - 2017-12-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-01-10 - 2035-06-15

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2011-09-01 - 2018-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB